This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Epidemiology of ulcerative colitis

Authoring team

Ulcerative colitis (UC) is most commonly seen in late adolescence and early adulthood although it may occur at any age. A small peak in incidence after the fifth decade has been observed in some populations (1).

The condition affects both males and females equally (1).

There is an annual incidence of 5-8/100,000 in most communities of Celtic and Anglo-Saxon origin in north-western Europe, North America and New Zealand. The prevalence of symptomatic disease in north-western Europe is 70-150/100,000. This disease is very uncommon in Asia and Africa. As in Crohn's disease, familial clustering may be seen.

NICE state (2):

  • around 296,000 people in the UK have a diagnosis of ulcerative colitis (Crohn's & Colitis UK)
  • the cause of ulcerative colitis is unknown
  • it can develop at any age, but peak incidence is between the ages of 15 and 25 years, with a second, smaller peak between 55 and 65 years (although this second peak has not been universally demonstrated).

Reference:

  1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018 Dec 23;390(10114):2769-78.
  2. NICE. Ulcerative colitis: management. NICE guideline NG130. Published May 2019, reviewed February 2025

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.